Category: Abbott LaboratoriesSyndicate content

Medtronic-Covidien merger may get caught in anti-inversion legislation | Medtech legal news for the week of July 21, 2014

July 21, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Abbott raises full-year guidance on strong Q2, but medtech lags

July 18, 2014 by Arezu Sarvestani

Abbott Labs reports a strong 2nd quarter driven in large part by diagnostics, but the medical device segment took a hit in U.S. sales, leading to a pretty flat quarter.

Abbott raises full-year guidance, but medtech numbers fail to impress

Illinois-based Abbott (NYSE:ABT) released a 2nd-quarter earnings report showing some strong momentum, but the healthcare giant's medical device sector didn't fare so well.

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.

Abbott CEO defends inversions amid corporate exodus furor

Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014

July 17, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Ocular Therapeutix sets terms for IPO; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B; Exo-suit maker ReWalk files for $57.5M IPO; Intersect ENT sets terms for $65M IPO

Ocular Therapeutix sets terms for IPO

July 11, 2014 by Brad Perriello

Ocular Therapeutix sets terms for IPO

Abbott reports meager medical device sales growth despite Q2 beats

July 16, 2014 by Brad Perriello

Abbott's medical device business posts meager growth for the 2nd quarter, despite overall sales and earnings coming in ahead of expectations.

Abbott reports meager medical device sales growth despite Q2 beats

Covidien shareholder files class action lawsuit blocking company's merger with Medtronic | The week in medtech M&A

July 16, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B

Shareholder files class action lawsuit to block Covidien-Medtronic merger

July 11, 2014 by Brad Perriello

Abbott to deal pharma line to Mylan for $5.3B

July 14, 2014 by Brad Perriello

Abbott agrees to deal its specialty and branded generic pharmaceutical line to Mylan for $5.3 billion.

Abbott to deal pharma line to Mylan for $5.3B

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp